The first Innovation Conference on the Diagnosis and Treatment of Lung Cancer Patients at Bellvitge Campus takes place

The main objective of today’s conference is to review the latest developments in the diagnosis and treatment of lung cancer, providing a space for the exchange of ideas between professionals in the field.

During the day there will be a series of talks organised into three thematic blocks: diagnosis and extension studies, treatment of early disease and treatment of advanced cancer.

WhatsApp Image 2024-02-16 at 12.24.33_v1

The Bellvitge Biomedical Research Institute (IDIBELL), together with the Catalan Institute of Oncology (ICO) and the University Hospital of Bellvitge (HUB), hold today Friday, February 16, the 1st Innovation Conference on the Diagnosis and Treatment of Patients with Lung Cancer. The conference is promoted by the Lung Functional Unit of the Bellvitge Campus and brings together nearly 100 professionals from the organising institutions, the regional hospitals and the primary care centres, to share and discuss the latest advances in the field.


The conference takes place in the auditorium of the University Hospital of Bellvitge and is coordinated by Dr. Ernest Nadal and Dr. Susana Padrones, IDIBELL researchers and medical specialists in the ICO and Hospital de Bellvitge, respectively. As a training activity, it is aimed especially at medical staff involved in the management of patients with lung cancer in the network of hospitals in the South Metropolitan Area linked to the ICO and the HUB, as well as other specialists with an interest in the pathology.


During the day there will be a series of talks organised into three thematic blocks. The first block on diagnosis and extension studies will discuss care circuits, advances in endoscopic diagnosis and non-surgical staging, the role of the nurse, and the management of the pulmonary nodule. The second block, dedicated to early disease, will address innovations in thoracic surgery and radiotherapy modalities with curative intent. Finally, the third and last section, focusing on advanced cancer, will review current developments in molecular studies and massive sequencing, precision medicine and targeted therapy, immunotherapy and the management of oligoprogression.


The Lung Functional Unit, which is organising the event, was created in 1998, and is the third functional unit of oncological care promoted by the ICO and the HUB. These functional units coordinate the interdisciplinary teams specialised in each type of cancer to facilitate the determination of an accurate and careful diagnosis, seeking to provide optimal care centred on patients and their families.


The initiative is supported by MSD, AstraZeneca, Roche, Pfizer, Takeda Pharmaceuticals, Johnson&Johnson and Bristol Myers Squibb.



The Bellvitge Biomedical Research Institute (IDIBELL) is a biomedical research center created in 2004. It is participated by the Bellvitge University Hospital and the Viladecans Hospital of the Catalan Institute of Health, the Catalan Institute of Oncology, the University of Barcelona and the City Council of L’Hospitalet de Llobregat.

IDIBELL is a member of the Campus of International Excellence of the University of Barcelona HUBc and is part of the CERCA institution of the Generalitat de Catalunya. In 2009 it became one of the first five Spanish research centers accredited as a health research institute by the Carlos III Health Institute. In addition, it is part of the “HR Excellence in Research” program of the European Union and is a member of EATRIS and REGIC. Since 2018, IDIBELL has been an Accredited Center of the AECC Scientific Foundation (FCAECC).

Scroll to Top